We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
If German generics maker Stada is looking for a large deal, Takeda’s reportedly for-sale European drugs could be a good target. But to hear Stada's CEO tell it, the company has plenty of choices.